A systematic review and meta-analysis of radiotherapy and particle beam therapy for skull base chondrosarcoma: TRP-chondrosarcoma 2024.
Front Oncol
; 14: 1380716, 2024.
Article
en En
| MEDLINE
| ID: mdl-38567162
ABSTRACT
Introduction:
Chondrosarcoma is a rare malignant bone tumor. Particle beam therapy (PT) can concentrate doses to targets while reducing adverse events. A meta-analysis based on a literature review was performed to examine the efficacy of PT and photon radiotherapy for skull base chondrosarcoma.Methods:
The meta-analysis was conducted using 21 articles published from 1990 to 2022.Results:
After PT, the 3- and 5-year overall survival (OS) rates were 94.1% (95% confidence interval [CI] 91.0-96.2%) and 93.9% (95% CI 90.6-96.1%), respectively, and the 3- and 5-year local control rates were 95.4% (95% CI 92.0-97.4%) and 90.1% (95% CI 76.8-96.0%), respectively. Meta-regression analysis revealed a significant association of PT with a superior 5-year OS rate compared to three-dimensional conformal radiotherapy (p < 0.001). In the studies used in the meta-analysis, the major adverse event of grade 2 or higher was temporal lobe necrosis (incidence 1-18%, median 7%).Conclusion:
PT for skull base chondrosarcoma had a good outcome and may be a valuable option among radiotherapy modalities. However, high-dose postoperative irradiation of skull base chondrosarcoma can cause adverse events such as temporal lobe necrosis.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Idioma:
En
Revista:
Front Oncol
Año:
2024
Tipo del documento:
Article
País de afiliación:
Japón